Search

Your search keyword '"Takasaki, Satoshi"' showing total 64 results
Start Over Author "Takasaki, Satoshi"
64 results on '"Takasaki, Satoshi"'

53. Renal Adenoma.

Author

Suzuki, Masafumi, Nikaido, Takashi, Ikegami, Masahiro, Kikuchi, Yasushi, Takasaki, Satoshi, Furusato, Masakuni, and Aizawa, Shigeo

Published
1989
Full Text
View/download PDF

60. A Study on the normal Structure of the human Liver, with special

Author

MATSUMOTO, Takeshiro, primary, KOMORI, Ryo, additional, MAGARA, Tadao, additional, UI, Tsuguo, additional, KAWAKAMI, Makio, additional, TOKUDA, Tadaaki, additional, TAKASAKI, Satoshi, additional, HAYASHI, Hirotaka, additional, Jo, Kensuke, additional, HANO, Hiroshi, additional, and TANAKA, Hisako, additional

Published
1979
Full Text
View/download PDF

61. The Japanese Journal of Gastroenterological Surgery

Author

NAKAMOTO, Minoru, primary, TAKAHASHI, Tsuneo, additional, IDE, Tetsuya, additional, MORINAGA, Yasuyoshi, additional, NARUSE, Masaru, additional, MIHO, Otomi, additional, TAKAHASHI, Masahito, additional, KATOH, Nobuo, additional, NAGAO, Fusahiro, additional, and TAKASAKI, Satoshi, additional

Published
1983
Full Text
View/download PDF

64. Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group.

Author

Hirabayashi Y, Munakata Y, Miyata M, Urata Y, Saito K, Okuno H, Yoshida M, Kodera T, Watanabe R, Miyamoto S, Ishii T, Nakazawa S, Takemori H, Ando T, Kanno T, Komagamine M, Kato I, Takahashi Y, Komatsuda A, Endo K, Murai C, Takakubo Y, Miura T, Sato Y, Ichikawa K, Konta T, Chiba N, Muryoi T, Kobayashi H, Fujii H, Sekiguchi Y, Hatakeyama A, Ogura K, Sakuraba H, Asano T, Kanazawa H, Suzuki E, Takasaki S, Asakura K, Sugisaki K, Suzuki Y, Takagi M, Nakayama T, Watanabe H, Miura K, and Mori Y

Subjects
Aged, Arthritis, Rheumatoid diagnostic imaging, Disease Progression, Female, Humans, Male, Middle Aged, Prospective Studies, Remission Induction methods, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy
Abstract

Objective: To evaluate the clinical and structural efficacy of tocilizumab (TCZ) during its long-term administration in patients with rheumatoid arthritis (RA)., Methods: In total, 693 patients with RA who started TCZ therapy were followed for 3 years. Clinical efficacy was evaluated by DAS28-ESR and Boolean remission rates in 544 patients. Joint damage was assessed by calculating the modified total Sharp score (mTSS) in 50 patients., Results: When the reason for discontinuation was limited to inadequate response or adverse events, the 1-, 2-, and 3-year continuation rates were 84.0%, 76.8%, and 72.2%, respectively. The mean DAS28-ESR was initially 5.1 and decreased to 2.5 at 6 months and to 2.2 at 36 months. The Boolean remission rate was initially 0.9% and increased to 21.7% at 6 months and to 32.2% at 36 months. The structural remission rates (ΔmTSS/year ≤ 0.5) were 68.8%, 78.6%, and 88.9% within the first, second, and third years, respectively. The structural remission rate at 3 years (ΔmTSS ≤ 1.5) was 66.0%, and earlier achievement of swollen joint count (SJC) of 1 or less resulted in better outcomes., Conclusions: TCZ was highly efficacious, and bone destruction was strongly prevented. SJC was an easy-to-use indicator of joint destruction.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results